Loading...
Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma (NHL), representing 30% of all lymphoma cases. Within the first 2-3 years following immunochemotherapy, 30-40% of patients will experience a relapse or a refractory disease, thereby exhibiting a poor prog...
Na minha lista:
| Udgivet i: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
D.A. Spandidos
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7416618/ https://ncbi.nlm.nih.gov/pubmed/32789017 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2103 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|